tiprankstipranks
Trending News
More News >
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
US Market

Prelude Therapeutics (PRLD) Income Statement

Compare
169 Followers

Prelude Therapeutics Income Statement

Last quarter (Q3 2025), Prelude Therapeutics's total revenue was $6.50M, an increase of 62.50% from the same quarter last year. In Q3, Prelude Therapeutics's net income was $-19.73M. See Prelude Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 7.00M$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 7.00M$ 0.00$ 0.00$ 0.00$ -542.00K
Operating Expenses
$ 146.71M$ 132.28M$ 123.54M$ 113.73M$ 58.76M
Depreciation and Amortization
$ 1.77M$ 1.17M$ 1.32M$ 915.00K$ 542.00K
EBITDA
$ -137.94M$ -131.11M$ -122.22M$ -112.82M$ -58.22M
Operating Income
$ -139.71M$ -132.28M$ -123.54M$ -113.73M$ -58.76M
Other Income/Expenses
$ 12.54M$ 10.44M$ 8.10M$ 2.04M$ 1.83M
Pretax Income
$ -127.17M$ -121.83M$ -115.44M$ -111.69M$ -56.93M
Net Income
$ -127.17M$ -121.83M$ -115.44M$ -111.69M$ -56.93M
Per Share Metrics
Basic EPS
$ -1.68$ -2.02$ -2.27$ -2.33$ -1.30
Diluted EPS
$ -1.68$ -2.02$ -2.27$ -2.33$ -1.30
Weighted Average Shares Outstanding
75.81M 60.36M 47.37M 47.60M 43.71M
Weighted Average Shares Outstanding (Diluted)
75.81M 60.36M 47.37M 47.60M 43.71M
Currency in USD

Prelude Therapeutics Earnings and Revenue History